Bli medlem
Bli medlem

Du är här

2016-12-20

TiGenix: Takeda makes €10 million equity investment in TiGenix

PRESS RELEASE

REGULATED INFORMATION
INSIDE INFORMATION

Takeda makes €10 million
equity investment in TiGenix

Leuven (BELGIUM) - December 20, 2016, [22:01]h CET - TiGenix NV (Euronext
Brussels and NASDAQ: TIG; "TiGenix"), an advanced biopharmaceutical company
focused on developing and commercializing novel therapeutics from its
proprietary platforms of allogeneic expanded stem cells, announced today that
it has exercised the option granted by Takeda under the licensing agreement
to make a €10 million equity investment in TiGenix. Takeda Pharmaceuticals
International AG will be subscribing 11,651,778 new ordinary shares (the "New
Shares") at an issue price of €0.858 (rounded) per New Share. The issue price
is equal to the average closing price of TiGenix's share on Euronext Brussels
over the 30 day period preceding the date on which the issuance of the New
Shares commenced (i.e., December 20, 2016) and represents a 23% premium over
today's closing price on Euronext Brussels.

On July 4, 2016, Takeda and TiGenix entered into an exclusive ex-U.S. license,
development and commercialization agreement for Cx601 for the treatment of
complex perianal fistulas in patients with Crohn's disease. The licensing
agreement also provided for Takeda to make an equity investment of €10
million in the share capital of TiGenix within the 12 months following the
date of the licensing agreement.

"We are pleased to welcome our partner Takeda as one of our key shareholders,"
said Eduardo Bravo, CEO of TiGenix. "These additional funds will further
strengthen our financial position allowing us to remain fully focused on
progressing with the marketing authorization application of Cx601 in Europe,
the launch of our Phase III trial to register Cx601 in the United States and
advancing with the other clinical assets in our pipeline," concluded Eduardo
Bravo.

In connection with the issuance of the New Shares and the resulting capital
increase, the board of directors has cancelled the preferential subscription
rights of existing shareholders for the benefit of Takeda Pharmaceuticals
International AG. The capital increase has been decided within the limits of
the authorized share capital in accordance with article 6 of the articles of
association of TiGenix.

The issuance of these New Shares is expected to take place by the end of the
first week of January 2017, provided that TiGenix has timely received the
proceeds of the private placement from Takeda. TiGenix shall request the
listing of the New Shares on Euronext Brussels. The New Shares will be
subject to a one-year lock-up, subject to certain exceptions.

For more information, please contact:

TiGenix
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix

TiGenix NV (Euronext Brussels&NASDAQ: TIG) is an advanced biopharmaceutical
company focused on developing and commercializing novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
Our lead product candidate from the adipose-derived stem cell technology
platform is Cx601, which is in registration with the European Medicines
Agency for the treatment of complex perianal fistulas in Crohn's disease
patients. Our adipose-derived stem cell product candidate Cx611 has completed
a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid
arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead
cellular product candidate, AlloCSC-01, is currently in a Phase II clinical
trial in Acute Myocardial Infarction (AMI). In addition, the second product
candidate from the cardiac stem cell-based platform acquired from
Coretherapix, AlloCSC-02, is being developed in a chronic indication. On July
4, 2016, TiGenix entered into a licensing agreement with Takeda, a large
pharmaceutical company active in gastroenterology, under which Takeda
acquired the exclusive right to commercialize Cx601 for complex perianal
fistulas outside the United States. TiGenix is headquartered in Leuven
(Belgium) and has operations in Madrid (Spain).

Forward-looking information

This press release may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in
which it operates. Certain of these statements, forecasts and estimates can
be recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that
are not historical facts. Such statements, forecasts and estimates are based
on various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made but
may or may not prove to be correct. Actual events are difficult to predict
and may depend upon factors that are beyond TiGenix's control. Therefore,
actual results, the financial condition, performance or achievements of
TiGenix, or industry results, may turn out to be materially different from
any future results, performance or achievements expressed or implied by such
statements, forecasts and estimates. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the date
of the publication of this press release. TiGenix disclaims any obligation to
update any such forward-looking statement, forecast or estimates to reflect
any change in TiGenix's expectations with regard thereto, or any change in
events, conditions or circumstances on which any such statement, forecast or
estimate is based, except to the extent required by applicable law.

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.